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Scientific summary
Background
Medication organisation devices (MODs) are a box or blister pack divided into days of the week with
several compartments per day to allow for different dose timings. They are intended to organise a patient’s
medication to facilitate correct medication taking. MODs are most frequently provided to older people,
often supported by NHS funds. Definitive evidence for either clinical effectiveness or cost-effectiveness is
lacking. A trial to fill this evidence gap presents design challenges; thus preliminary research is required.
Objectives
The aim was to design and test the feasibility of conducting a randomised controlled trial (RCT) of the
clinical effectiveness and cost-effectiveness of MODs. The objectives were to:
1. identify the most effective method of participant recruitment
2. estimate the prevalence of intentional non-adherence within an older population
3. estimate the prevalence and magnitude of unintentional non-adherence within a 3-week period
within an older population
4. describe the functional abilities of an older population
5. provide a point estimate of the effect size of MODs relative to usual packaging
6. describe the feasibility and participant acceptability of trial participation
7. describe the feasibility of collecting the data necessary to conduct an economic evaluation.
Methods
The study comprised two phases: trial design and trial testing. Trial design included a systematic review,
supplementary literature searching and focus groups. The systematic review included MOD studies of any
design reporting any of the following outcomes: medication adherence, health outcomes, health-related
quality of life, health or social care utilisation, dispensing or administration errors or prescribing- or medicine
supply-related costs. Search terms comprising medical subject headings, free text and trade names were
applied to electronic databases. Duplicate independent data extraction was undertaken. Supplementary
searches informed characteristics of the study tested in phase 2. Focus groups with patients, carers and
health-care professionals refined the proposed study design prior to testing.
The trial undertaken in phase 2 was a randomised 2 × 2 factorial design to test the effect of MODs compared
with medication dispensed in usual packaging and of weekly compared with monthly medication supply.
Two methods of recruitment were trialled: passive postal recruitment by a medical practice and active
recruitment by a researcher placed in a medical practice. Six medical practices and the 11 neighbouring
pharmacies were recruited. The six medical practices were matched by patient list size and equally allocated
to the recruitment methods, each of which was trialled for 3 weeks, after which all practices undertook
passive recruitment. Patients were eligible for the study if they were aged ≥ 75 years, were prescribed three
or more solid oral dosage form medications [of which at least two were from a defined list that was intended
for electronic adherence monitoring (EAM)] and were capable of providing informed consent. Patients with a
life expectancy of less than 12 months, current other clinical trial involvement, experience of using a MOD or
a diagnosis of Parkinson’s disease, a severe mental health disorder or other situation deemed inappropriate
by the health-care team were excluded. Those not self-administering their medication, who were using a
medication organisation strategy incompatible with trial participation or who were intentionally non-adherent
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were also excluded. Intentionally non-adherent participants were excluded by using their responses to a
questionnaire. A 3-week dosage unit count was undertaken for the remaining participants and those
demonstrating perfect adherence were excluded. The remaining unintentionally non-adherent participants
were randomised to one of the four arms. The primary outcome was percentage adherence,
as defined by dosage unit count. Other outcomes explored were self-reported health and quality of life,
autonomy and satisfaction, mortality and costs.
Evaluation of the feasibility and acceptability of the interventions and trial design was undertaken using
questionnaires and group discussions with participants and health-care professionals involved in the study.
Results
The systematic review identified that studies on MODs are largely of poor quality and that the evidence
regarding the effects of MODs is contradictory. The majority of studies reported adherence but no health
outcomes. Those studies reporting both adherence and health outcomes did not unequivocally report a
positive relationship; some studies reported increased hospitalisation associated with MODs. No study
reported any humanistic outcomes such as health-related quality of life.
The literature searches determined the validated tools that would be used for assessing patient functional
ability and identified three potential candidates for EAM during the RCT element of the feasibility study.
However, none of these manufacturers was able to produce a working version in the duration of
the study.
The pre-trial focus groups largely considered the proposed trial design feasible and acceptable, the three
MODs selected were Nomad™ (Surgichem Ltd, Cheshire, UK), Nomad XL™ (Surgichem Ltd, Cheshire, UK)
and Venalink™ (Venalink, Flintshire, UK). Disparity between the focus groups and literature was greatest
regarding the minimum age for patient recruitment, with the suggested minimum age ranging from
50 years (health-care professionals) to 75 years (literature). Furthermore, pharmacists reported that the
frequency with which MODs are initiated increases from the age of 70 years. The RCT element of the
feasibility study retained the 75 years threshold that was determined a priori.
Active recruitment yielded a higher consent rate but passive recruitment was more cost-effective at a cost
of £2528 and £506 per participant recruited, respectively. The most significant attrition during recruitment
was at the stage of determining eligibility for electronic medication adherence monitoring, which excluded
64.9% of the potentially eligible sample, followed by ineligibility because patients already used a MOD,
which removed 45.6% from the remaining sample.
The prevalence of intentional non-adherence was 24.7% (95% CI 19.7% to 29.6%). Of the remaining
76 participants, 46.1% (95% CI 34.8% to 57.3%) were unintentionally non-adherent after 3 weeks of
monitoring. The population was not cognitively impaired and the majority had adequately corrected vision.
Manual dexterity varied, with 41.4% (95% CI 23.4% to 59.3%) having poorer function than normative
values for their age and sex.
Mean adherence over the 8-week monitoring period exceeded 95% for all study arms and there was
no indication of a difference between the study arms. Similarly, the post-trial participant questionnaire
identified a relatively high level of satisfaction with all trialled methods and frequency of medication supply.
The majority of participants and carers reported no change in confidence and autonomy. There was no
indication of a difference between study arms in any of these outcomes. Five adverse events (AEs) or serious
adverse events were identified in the MOD study arms, compared with none in the usual packaging arms.
These comprised three falls, one hypoglycaemic episode and one temporary incapacitation.
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Data to estimate health economic outcomes were successfully collected from participants and health and
social care organisations. There was no discernible difference between the four study arms; the mean
intervention cost was £20 per month greater for MOD monthly relative to usual supply monthly. Given
the lower cost of monthly usual care, it dominated other study arms.
Conclusions
l Medication organisation devices were initiated for participants identified as unintentionally non-adherent
and are widely used in routine practice for this purpose. The AEs observed in the MOD arms indicate that
they may be associated with an increase in medication dose-related AEs.
l As a feasibility study, the implications for a future study are that maintaining the minimum recruitment
age at 75 years resulted in over one-third of patients being ineligible for study participation because
they already used a MOD. It is clear, therefore, that a subsequent study must have a lower age
threshold in order to include participants of the age at which MODs are initiated in usual care. The
ethical restriction of being unable to recruit patients already receiving a MOD means that the patients
most likely to demonstrate benefit may have been excluded. It is therefore likely that the results of this
feasibility study and any definitive trial provide a conservative estimate of any MOD benefits.
l Electronically monitoring adherence in the usual-care environment remains a technological challenge.
l Recruitment using invitation letters is more cost-effective than personal recruitment by researchers.
Recommendations for research
1. The relationship between MODs and AEs requires further exploration as adherence may not be the
most appropriate primary outcome measure; a health outcome such as quality of life or health and
social care use may be more appropriate.
2. A trial fully examining the costs and effects of MODs (both positive and negative) is necessary. Such
a study should stratify participants by history of hospital admissions or by health and social care use.
3. Further work to develop an EAM system compatible with usual medication packaging is necessary.
4. The relationship between MODs, medication adherence and health outcomes requires
further investigation.
Funding
This project was funded by the NIHR Health Technology Assessment programme and will be published in
full in Health Technology Assessment; Vol. 20, No. 50. See the NIHR Journals Library website for further
project information.
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